LivaNova’s (LIVN) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $75.00 price objective on the stock.

A number of other research firms have also recently weighed in on LIVN. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 23rd. Finally, Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Trading Down 0.2 %

NASDAQ:LIVN opened at $50.64 on Tuesday. LivaNova has a one year low of $43.15 and a one year high of $64.47. The business has a fifty day moving average price of $49.05 and a 200-day moving average price of $49.97. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 120.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. Central Pacific Bank Trust Division purchased a new position in LivaNova in the third quarter valued at $178,000. Captrust Financial Advisors purchased a new position in shares of LivaNova in the 3rd quarter valued at about $217,000. Sanctuary Advisors LLC acquired a new position in LivaNova in the 3rd quarter worth about $219,000. Edgestream Partners L.P. purchased a new position in LivaNova during the third quarter worth approximately $244,000. Finally, GSA Capital Partners LLP acquired a new stake in LivaNova in the third quarter valued at approximately $292,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.